Clinical trial
Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of…
NCT00263549 · Allergopharma GmbH & Co. KG, Industry · Completed
Key facts
| NCT number | NCT00263549 |
|---|---|
| Title | Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis |
| Official title | Multicenter Study for Evaluation of Efficacy and Safety of Perennial Specific Immunotherapy With a Depot House Dust Mite Allergen Extract (D. Pteronyssinus 100%) in Patients With House Dust Mite Sensitivity |
| Lead sponsor | Allergopharma GmbH & Co. KG, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | House Dust Mite Allergy |
| Intervention type | Biological |
| Interventions | House dust mite Novo Helisen Depot |
| Start date | Sep 1, 2002 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2006 |
| First posted | Dec 9, 2005 |
| Last update posted | Feb 11, 2013 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: